The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid
Date
2012
Authors
Zhu R.
Kiser J.J.
Seifart H.I.
Werely C.J.
Mitchell C.D.
D'Argenio D.Z.
Fletcher C.V.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
The roles of the NAT2 genotype and enzyme maturation on isoniazid pharmacokinetics were investigated in South African infants with perinatal HIV exposure enrolled in a randomized, double-blind, controlled trial of isoniazid for prevention of tuberculosis disease and latent infection. Plasma concentration-time measurements of isoniazid from 151 infants (starting at 3-4 months of age) receiving isoniazid 10 to 20 mg/kg/d orally during the course of the 24-month study were incorporated in a population analysis along with NAT2 genotype, body weight, age, and sex. The results showed a different NAT2 enzyme maturation profile for each of the 3 acetylation groups, with the 70-kg body weight-normalized typical apparent clearance for the fast and intermediate acetylators increasing from 14.25 L/h and 10.88 L/h at 3 months of age to 22.84 L/h and 15.58 L/h at 24 months of age, respectively, with no significant change in the apparent clearance of the slow group during this period. A hypothesis is proposed to explain the genotype-dependent enzyme maturation processes for the NAT2 enzyme. © 2012 The Author(s).
Description
Keywords
enzyme maturation, genetic polymorphism, Infants, pharmacogenetics, population pharmacokinetics
Citation
Journal of Clinical Pharmacology
52
4
511
519
52
4
511
519